Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

Merck (MRK) stock gains as new oral HIV tablet matches Gilead's (GILD) three-drug once-daily HIV pill Biktarvy in a Phase 3 ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

SAN FRANCISCO -- Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF; Biktarvy) or ...

Islatravir (MK-8591) is an investigational nucleoside reverse transcription translocation inhibitor. Credit: Getty Images. The Food and Drug Administration (FDA) has placed clinical holds on studies ...

Concerns about lower lymphocyte levels in HIV with the once-daily oral drug islatravir in combination with doravirine changed the trajectory of clinical trial plans that are now back on track, ...

The US Food and Drug Administration (FDA) has stopped trials of oral and implant formulations of islatravir for HIV, the investigational drug's developer, Merck and Co, announced in a press release.